Max Healthcare

Why is Max Healthcare Institute Ltd falling/rising?

As of 29-Jul, Max Healthcare Institute Ltd's stock price is rising to 1,111.25, driven by strong performance, positive debt servicing ability, healthy growth prospects, and high institutional holdings. Despite a decline in investor participation, the stock remains liquid, reflecting ongoing interest.

As of 29-Jul, Max Healthcare Institute Ltd's stock price is rising, currently at 1,111.25, reflecting a change of 6.4 (0.58%) upward. This increase can be attributed to several factors. The stock has demonstrated strong performance over the past week, with a return of +2.74%, significantly outperforming the Sensex, which only gained +1.17% in the same period. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>Moreover, the company has shown a robust ability to service its debt, with a low Debt to EBITDA ratio of 1.55 times, which is a positive indicator for investors. The long-term growth prospects appear healthy, as evidenced by an annual growth rate of 27.30% in net sales and a 53.33% increase in operating profit. Furthermore, the high institutional holdings at 71.73% suggest that knowledgeable investors have confidence in the company's fundamentals.<BR><BR>Despite a recent decline in investor participation, with delivery volume falling by 34.67% against the 5-day average, the stock remains liquid enough for trading, indicating that there is still sufficient interest in the stock. Overall, these factors contribute to the rising stock price of Max Healthcare Institute Ltd.

Which are the latest news on Max Healthcare?

Should I buy, sell or hold Max Healthcare Institute Ltd?

What does Max Healthcare do?

Max Healthcare Institute Ltd is a large-cap hospital company in India, reporting net sales of ₹2,143 Cr and a net profit of ₹342 Cr for the quarter ending March 2026. Key financial metrics include a P/E ratio of 66.00 and a market cap of ₹98,181 Cr.

Overview:<BR>Max Healthcare Institute Ltd operates in the hospital industry and is categorized as a large-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Infinitum Technologies Private Limited" in New Delhi, India, on June 18, 2001. It changed its name to "Max Healthcare Institute Private Limited" following a Fresh Certificate of Incorporation dated June 28, 2002. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,143 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 342 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 98,181 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 66.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.15%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 13.79%<BR>- Price to Book: 9.09<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

How big is Max Healthcare?

As of 10th June, Max Healthcare Institute Ltd has a market capitalization of 98,181.00 Cr, with recent net sales of 8,373.45 Cr and net profit of 1,442.41 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Max Healthcare Institute Ltd has a market capitalization of 98,181.00 Cr and is classified as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8,373.45 Cr, while the sum of Net Profit for the same period is 1,442.41 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 9,380.87 Cr, and Total Assets are valued at 15,186.44 Cr.

Who are in the management team of Max Healthcare?

The management team of Max Healthcare includes Chairman Abhay Soi, along with several directors: Anil Bhatnagar, K Narasimha Murthy, Mahendra Lodha, Michael Thomas Neeb, Pranav Amin, Amrita Gangotra, and Narayan Seshadri, providing diverse expertise and governance.

The management team of Max Healthcare includes the following individuals:<BR><BR>1. **Abhay Soi** - Chairman / Executive Director<BR>2. **Anil Bhatnagar** - Non-Executive & Non-Independent Director<BR>3. **K Narasimha Murthy** - Independent Non-Executive Director<BR>4. **Mahendra Lodha** - Independent Non-Executive Director<BR>5. **Michael Thomas Neeb** - Independent Non-Executive Director<BR>6. **Pranav Amin** - Independent Non-Executive Director<BR>7. **Amrita Gangotra** - Independent Non-Executive Director<BR>8. **Narayan Seshadri** - Non-Executive Director<BR><BR>This team brings a diverse range of expertise and governance to the company.

Who are the peers of the Max Healthcare?

Max Healthcare's peers include Apollo Hospitals, Fortis Health, Aster DM Health, Narayana Hrudaya, Global Health, Krishna Institute, Dr. Agarwal's Health, Rainbow Children, and Health.Global. In terms of management risk, growth, and capital structure, Max Healthcare shows average performance, with a 1-year return of -14.68%, the lowest among its peers.

Peers: The peers of Max Healthcare are Apollo Hospitals, Fortis Health., Aster DM Health., Narayana Hrudaya, Global Health, Krishna Institu., Dr Agarwal's Hea, Rainbow Child., and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., and Rainbow Child., while Good management risk is found at Aster DM Health. and Fortis Health. Average management risk is present at Max Healthcare, Dr Agarwal's Hea, and Health.Global. For growth, Excellent growth is noted at Apollo Hospitals, Max Healthcare, Fortis Health., and Narayana Hrudaya, while Below Average growth is seen at Aster DM Health., Global Health, Krishna Institu., and Rainbow Child. Average growth is reported for Dr Agarwal's Hea. In terms of capital structure, Excellent capital structure is held by Max Healthcare and Global Health, while Good capital structure is found at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, Krishna Institu., and Rainbow Child., and Average capital structure is noted at Apollo Hospitals and Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 27.83%, while Max Healthcare has the lowest at -14.68%. This indicates that Max Healthcare's return is significantly lower than its peers. Additionally, the six-month return is negative for Max Healthcare, Dr Agarwal's Hea, and Health.Global.

Are Max Healthcare Institute Ltd latest results good or bad?

Max Healthcare Institute Ltd's latest results show strong operational performance with a net profit increase and revenue growth, but concerns about stock underperformance, rising interest expenses, and high valuations suggest caution for investors.

Max Healthcare Institute Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹342.22 crore for Q4 FY26, which is a 13.72% increase quarter-on-quarter (QoQ) and a 7.28% increase year-on-year (YoY). Revenue also saw growth, reaching ₹2,142.89 crore, up 3.65% QoQ and 12.21% YoY. Additionally, the operating margin improved to 28.30%, marking the highest quarterly margin in recent times.<BR><BR>However, there are significant concerns. The company's stock has underperformed compared to its sector peers, declining 11.09% over the past year while the hospital sector gained 19.53%. The rising interest expenses, which surged to ₹66.66 crore, and a high price-to-earnings ratio of 73x raise questions about the sustainability of its premium valuation. Furthermore, the Mojo Score of 42 out of 100 indicates a "SELL" rating, reflecting worries about expensive valuations and flat near-term financial trends.<BR><BR>In summary, while the operational performance shows strength, the financial structure and market sentiment suggest caution for investors.

When is the next results date for Max Healthcare Institute Ltd?

The next results date for Max Healthcare Institute Ltd is 05 February 2026.

The next results date for Max Healthcare Institute Ltd is scheduled for 05 February 2026.

Is Max Healthcare technically bullish or bearish?

As of December 4, 2025, Max Healthcare's trend has shifted to bearish with moderate strength, supported by bearish signals from the MACD, KST, and moving averages, despite some mixed signals on the monthly timeframe.

As of 4 December 2025, the technical trend for Max Healthcare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming a bearish trend. The Bollinger Bands indicate a bearish outlook on the weekly timeframe, while the monthly indicators show a mix of mildly bearish and mildly bullish signals, suggesting some divergence. Overall, the bearish trend is reinforced by the recent price action, with a notable decline in the past week and month compared to the Sensex.

How has been the historical performance of Max Healthcare?

Max Healthcare has experienced substantial growth from Mar'20 to Mar'25, with net sales increasing from 1,059.03 Cr to 7,028.46 Cr, and profit after tax rising from 12.91 Cr to 1,075.88 Cr. Total assets grew from 3,973.66 Cr to 15,186.44 Cr, reflecting the company's successful expansion strategy.

Answer:<BR>Max Healthcare has shown significant growth in its historical performance, particularly in net sales, which increased from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. The total expenditure, excluding depreciation, grew from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has similarly improved, climbing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax increased from 12.78 Cr in Mar'20 to 1,406.37 Cr in Mar'25. The profit after tax also saw a rise, reaching 1,075.88 Cr in Mar'25 compared to 12.91 Cr in Mar'20. The company's earnings per share (EPS) increased from 1.1 in Mar'20 to 11.07 in Mar'25, showcasing enhanced profitability per share. On the balance sheet, total assets grew from 3,973.66 Cr in Mar'20 to 15,186.44 Cr in Mar'25, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,459.00 Cr in Mar'25, although cash flow from investing activities showed a negative trend at -1,614.00 Cr.<BR><BR>Breakdown:<BR>Max Healthcare's financial performance has demonstrated remarkable growth over the years, particularly in net sales, which surged from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This growth in revenue is accompanied by a corresponding increase in total operating income, which reached 7,028.46 Cr in Mar'25, up from 1,059.03 Cr in Mar'20. The company's total expenditure also rose significantly, from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, reflecting the costs associated with scaling operations. Operating profit (PBDIT) has shown a strong upward trajectory, increasing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax improved from 12.78 Cr to 1,406.37 Cr in the same period. The profit after tax reached 1,075.88 Cr in Mar'25, a substantial increase from 12.91 Cr in Mar'20. The earnings per share (EPS) also rose significantly, indicating improved profitability for shareholders. On the balance sheet, total assets expanded from 3,973.66 Cr to 15,186.44 Cr, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr, reflecting the company's growth strategy. Additionally, cash flow from operating activities improved to 1,459.00 Cr in Mar'25, despite a negative cash flow from investing activities of -1,614.00 Cr, indicating ongoing investments in growth.

Who are the top shareholders of the Max Healthcare?

The top shareholders of Max Healthcare include Abhay Soi with 23.73%, Foreign Institutional Investors holding 54.74%, and mutual funds with 13.38%. The Government of Singapore is the largest public shareholder at 5.69%, while individual investors own 3.31%, with no pledged promoter holdings.

The top shareholders of Max Healthcare include a mix of institutional and individual investors. The largest shareholder is Abhay Soi, who holds 23.73% of the company. Foreign Institutional Investors (FIIs) are significant shareholders as well, collectively holding 54.74% of the shares, represented by 1020 FIIs. Additionally, mutual funds have a presence with 13.38% held across 33 schemes. The Government of Singapore is the highest public shareholder, owning 5.69%. Individual investors collectively hold 3.31% of the shares. Notably, there are no pledged promoter holdings.

Is Max Healthcare overvalued or undervalued?

As of October 29, 2021, Max Healthcare Institute Ltd. is considered very expensive with a PE ratio of 100.29, significantly higher than its peers, indicating it may be overvalued despite a 43% return over the past year compared to the Sensex's 7.55%.

As of 29 October 2021, the valuation grade for Max Healthcare Institute Ltd. moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE Ratio of 100.29, a Price to Book Value of 12.11, and an EV to EBITDA of 62.71. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Max Healthcare's valuation appears steep, as it has a higher PE ratio than many competitors in the healthcare sector. For instance, while Max Healthcare's PE stands at 100.29, other industry players typically exhibit lower ratios, indicating that investors may be paying a high price for expected growth that may not materialize. Notably, the company's stock has outperformed the Sensex over the past year, with a return of 43% compared to the Sensex's 7.55%, which may have contributed to the inflated valuation.

Has Max Healthcare declared dividend?

Max Healthcare Institute Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of August 23, 2024. The company has shown significant price appreciation over the years, particularly with a total return of 220.75% over three years.

Max Healthcare Institute Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 6.09%, with a dividend return of 0%, resulting in a total return of 6.09%.<BR><BR>For the 1-year period, the price return was 40.24%, the dividend return was 0.19%, leading to a total return of 40.43%.<BR><BR>Over the 2-year period, the price return was 122.44%, with a dividend return of 0.42%, culminating in a total return of 122.86%.<BR><BR>In the 3-year period, the price return reached 220.06%, while the dividend return was 0.69%, resulting in a total return of 220.75%.<BR><BR>For the 4-year period, the price return was 373.32%, with a dividend return of 0.98%, leading to a total return of 374.3%.<BR><BR>In the 5-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Max Healthcare has declared a dividend, which contributes to its total returns, particularly noticeable over longer periods. The company shows strong price appreciation, especially in the 3 to 4-year periods, despite lower dividend contributions.